Caltech - NanoSystems Biology Cancer Center

Caltech - NanoSystems Biology Cancer Center
Type Disciplines
Private University Nanomedicine Nanobiotechnology
Address Postal Code
Caltech Chemistry
127-72 1200 East California Blvd.
City State / Province
Pasadena California
E-mail Country
Web Phone
link (626) 395 8920

The Nanosystems Biology Cancer Center (NSBCC) is organized to take advantage of the state-of-the-art in chemistry, materials, and physics of nanotechnology science and engineering, the state-of-the-art in systems biology approach to health and disease, and the state-of-the-art in the science, technology, and clinical applications of cancer biology.

The NSBCC is Directed by Professor James R. Heath (Caltech) and co-directed by Dr. Leroy Hood (Institute for Systems Biology [Seattle, WA]) and Professor Michael Phelps (UCLA Geffen School of Medicine and Department of Molecular & Medical Pharmacology). The NSBCC is also aligned with UCLA’s Jonsson Comprehensive Cancer Center.

The concept behind the NSBCC is that measurement and analysis needs of systems approaches to cancer, ranging from cancer biology to clinical oncololgy, should drive the nature and direction technology development. Specific cancer projects within the center are focused around prostate and ovarian cancers, melanoma, and glioblastoma, but the technologies being developed to help understand and treat these cancers are intended to serve as a general class of technologies for all cancers.

The goals of early detection of ovarian and prostate cancers will be achieved through (1) the identification of a panel of organ-specific, secreted biomarkers that serve as sentinels for reporting the health status of the diseased organs; (2) the development of relatively small molecule, high affinity protein capture agents as probes against those secreted proteins; and (3) the development of high throughput, real time, label-free nanoelectronic/microfluidics sensor arrays for quantitating those protein levels through serum analysis , diagnostic approaches for following the positive and adverse responses of therapy.

Contact:  Director, James R. Heath

Related Content